Michael Gelband’s Nu Skin NUS Stock Holding History

Michael Gelband’s Portfolio NUS Stock Details NUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$616K	Buy	116,744 +38,735	+50%	+$248K	﹤0.01%	1187
2026 Q1	$568K	Buy	+78,009	New	+$706K	﹤0.01%	1158
2025 Q2	–	Sell	-19,985	Closed	-$145K	–	1822
2025 Q1	$145K	Sell	19,985 -168,317	-89%	-$1.22M	﹤0.01%	1326
2024 Q4	$1.3M	Sell	188,302 -3,301	-2%	-$22.7K	0.01%	860
2024 Q3	$1.41M	Buy	+191,603	New	+$1.79M	0.01%	856
2023 Q4	–	Sell	-143,733	Closed	-$3.05M	–	1874
2023 Q3	$3.05M	Buy	143,733 +85,927	+149%	+$2.23M	0.03%	531
2023 Q2	$1.92M	Buy	+57,806	New	+$2.13M	0.02%	820
2022 Q1	–	Sell	-179,605	Closed	-$9.12M	–	2535
2021 Q4	$9.12M	Buy	179,605 +146,504	+443%	+$6.51M	0.09%	249
2021 Q3	$1.34M	Buy	33,101 +15,360	+87%	+$777K	0.02%	894
2021 Q2	$1M	Buy	17,741 +12,814	+260%	+$729K	0.01%	1009
2021 Q1	$261K	Buy	+4,927	New	+$268K	﹤0.01%	1744
2020 Q4	–	Sell	-10,861	Closed	-$544K	–	2256
2020 Q3	$544K	Sell	10,861 -11,571	-52%	-$549K	0.01%	966
2020 Q2	$858K	Buy	22,432 +11,998	+115%	+$386K	0.02%	820
2020 Q1	$228K	Buy	+10,434	New	+$314K	0.01%	736

Other funds holding NUS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

CAS

Coppell Advisory Solutions Coppell, Texas $1.21B AUM 20.39% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

PGCM

Prescott Group Capital Management Tulsa, Oklahoma $1.16B AUM 53.61% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Michael Gelband's NUS Position: Q2 2026 in Review

Michael Gelband increased its Nu Skin (NUS) stake by 50% in Q2 2026, buying an estimated $248K and bringing the position to 116,744 shares worth $616K. The position accounts for ﹤0.01% of the portfolio, ranked #1187.

Michael Gelband first reported a position in NUS in Q1 2020 and has held it in 14 quarters since. The position peaked at $9.12M in Q4 2021. 161 funds tracked by Wall St. Rank hold NUS as of Q2 2026.

Michael Gelband held 116,744 shares of Nu Skin worth $616K as of Q2 2026.
Michael Gelband bought 38,735 Nu Skin shares in Q2 2026, an estimated $248K.
Nu Skin made up ﹤0.01% of Michael Gelband's portfolio in Q2 2026, its #1187 holding.
Michael Gelband first reported a position in Nu Skin in Q1 2020 and has held it in 14 quarters since.
Michael Gelband's Nu Skin position peaked at $9.12M in Q4 2021.
161 funds tracked by Wall St. Rank held Nu Skin as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.